Zurcher Kantonalbank Zurich Cantonalbank Boosts Stake in ICU Medical, Inc. (NASDAQ:ICUI)

Zurcher Kantonalbank Zurich Cantonalbank grew its stake in ICU Medical, Inc. (NASDAQ:ICUI) by 16.6% during the second quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The firm owned 5,514 shares of the medical instruments supplier’s stock after acquiring an additional 786 shares during the quarter. Zurcher Kantonalbank Zurich Cantonalbank’s holdings in ICU Medical were worth $655,000 at the end of the most recent quarter.

Several other large investors have also recently made changes to their positions in ICUI. CWM LLC grew its stake in ICU Medical by 341.2% in the fourth quarter. CWM LLC now owns 578 shares of the medical instruments supplier’s stock valued at $58,000 after purchasing an additional 447 shares during the last quarter. M&T Bank Corp raised its stake in shares of ICU Medical by 5.9% during the 4th quarter. M&T Bank Corp now owns 4,938 shares of the medical instruments supplier’s stock worth $493,000 after acquiring an additional 277 shares in the last quarter. Maryland State Retirement & Pension System purchased a new stake in ICU Medical during the fourth quarter valued at approximately $890,000. Charles Schwab Investment Management Inc. boosted its stake in ICU Medical by 14.1% in the fourth quarter. Charles Schwab Investment Management Inc. now owns 192,773 shares of the medical instruments supplier’s stock valued at $19,227,000 after acquiring an additional 23,816 shares in the last quarter. Finally, Jump Financial LLC purchased a new position in ICU Medical in the fourth quarter worth $352,000. 96.10% of the stock is owned by institutional investors.

ICU Medical Stock Performance

Shares of NASDAQ ICUI opened at $161.19 on Friday. The stock has a market cap of $3.93 billion, a price-to-earnings ratio of -65.79 and a beta of 0.69. ICU Medical, Inc. has a 12 month low of $78.28 and a 12 month high of $166.46. The company has a 50 day simple moving average of $138.23 and a two-hundred day simple moving average of $116.24. The company has a current ratio of 2.41, a quick ratio of 1.08 and a debt-to-equity ratio of 0.76.

ICU Medical (NASDAQ:ICUI) last released its quarterly earnings data on Wednesday, August 7th. The medical instruments supplier reported $1.56 earnings per share for the quarter, beating analysts’ consensus estimates of $1.00 by $0.56. ICU Medical had a positive return on equity of 5.01% and a negative net margin of 3.07%. The business had revenue of $596.50 million during the quarter, compared to analyst estimates of $556.64 million. During the same quarter last year, the business posted $1.58 EPS. The company’s revenue was up 8.6% on a year-over-year basis. As a group, analysts predict that ICU Medical, Inc. will post 3.76 earnings per share for the current year.

Insider Buying and Selling at ICU Medical

In other news, VP Virginia Ruth Sanzone sold 2,050 shares of the firm’s stock in a transaction that occurred on Thursday, August 8th. The shares were sold at an average price of $144.11, for a total transaction of $295,425.50. Following the sale, the vice president now owns 4,482 shares of the company’s stock, valued at approximately $645,901.02. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. In related news, VP Virginia Ruth Sanzone sold 2,050 shares of the stock in a transaction on Thursday, August 8th. The shares were sold at an average price of $144.11, for a total transaction of $295,425.50. Following the sale, the vice president now directly owns 4,482 shares of the company’s stock, valued at $645,901.02. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link. Also, CEO Vivek Jain sold 12,000 shares of ICU Medical stock in a transaction on Tuesday, September 3rd. The shares were sold at an average price of $163.46, for a total transaction of $1,961,520.00. Following the completion of the transaction, the chief executive officer now directly owns 104,593 shares of the company’s stock, valued at approximately $17,096,771.78. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 28,552 shares of company stock valued at $4,537,802. 6.70% of the stock is owned by company insiders.

Analysts Set New Price Targets

ICUI has been the topic of several research analyst reports. Needham & Company LLC restated a “hold” rating on shares of ICU Medical in a research note on Thursday, August 8th. KeyCorp boosted their price target on ICU Medical from $136.00 to $147.00 and gave the stock an “overweight” rating in a research note on Thursday, August 8th. Finally, Raymond James increased their price objective on shares of ICU Medical from $135.00 to $158.00 and gave the company an “outperform” rating in a research report on Thursday, August 8th. Two investment analysts have rated the stock with a hold rating and three have given a buy rating to the company’s stock. According to MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and an average price target of $138.33.

ICU Medical Company Profile

ICU Medical, Inc, together with its subsidiaries, develops, manufactures, and sells medical devices used in infusion therapy, vascular access, and vital care applications worldwide. Its infusion therapy products include needlefree products under the MicroClave, MicroClave Clear, and NanoClave brands; Neutron catheter patency devices; ChemoClave and ChemoLock closed system transfer devices, which are used to limit the escape of hazardous drugs or vapor concentrations, block the transfer of environmental contaminants into the system, and eliminates the risk of needlestick injury; Tego needle free connectors; Deltec GRIPPER non-coring needles for portal access; and ClearGuard, SwabCap, and SwabTip disinfection caps.